Beamion PANTUMOR-1: A phase II, multicenter, multicohort, open-label trial to evaluate the efficacy and safety of the oral HER2-selective tyrosine kinase inhibitor zongertinib for the treatment of

Authors: Alison M. Schram, Timothy Dudley Clay, Hans Prenen, John J. Park, Lukas Lunger, Joanna Hussain, Daniela Maier, Shigehisa Kitano, Ecaterina Elena Dumbrava, Hyung-Don Kim, Mariano Ponz-Sarvise, Ye Guo

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps3187

Source: Full article

---

Abstract

TPS3187